Co-Diagnostics Corp (CODX) - שולי רווח נקי ממכירות

Co-Diagnostics, Inc. (CODX) develops affordable molecular tests for the rapid diagnosis of infections. However, declining demand for COVID-19 testing and the costs associated with certifying a new platform have resulted in losses. The net sales margin reflects the impact of these factors, with -7252.60 serving as the final level marker. Growth prospects now depend on the launch of home PCR systems and an increase in the sale of consumables.
פילוחי מדדים מקיפים ואנליטיקה עבור CoDx (CODX)

To build a high-quality portfolio, I use this indicator as an operational efficiency filter. The metric determines the share of net profit in total revenue after deducting all expenses. For Co-Diagnostics, Inc. (CODX), this reflects the profitability of PCR system sales and diagnostic tests. Analyzing the net commercial margin allows for the timely detection of declining sales profitability, while sharp fluctuations in this net commercial margin signal hidden risks.